# Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)

> **NCT02491073** · — · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 71 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **OTHER:** blood draw

## Key facts

- **NCT ID:** NCT02491073
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2018-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02491073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02491073, "Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02491073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*